Industry ranking
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2024 - 31 Dec 2024 | 30 Jan 2025 | 25 | 64% | 31% | 5% | 10% |
| 01 Jan 2024 - 30 Jun 2024 | 24 Jul 2024 | 32 | 64% | 28% | 8% | 14% |
| 01 Jul 2023 - 31 Dec 2023 | 22 Jan 2024 | 27 | 64% | 31% | 5% | 26% |
| 01 Jan 2023 - 30 Jun 2023 | 26 Jul 2023 | 28 | 63% | 30% | 7% | 25% |
| 01 Jul 2022 - 31 Dec 2022 | 25 Jan 2023 | 23 | 72% | 25% | 3% | 16% |
| 01 Jan 2022 - 30 Jun 2022 | 28 Jul 2022 | 28 | 66% | 30% | 4% | 7% |
| 01 Jul 2021 - 31 Dec 2021 | 27 Jan 2022 | 27 | 65% | 33% | 2% | 17% |
| 01 Jan 2021 - 30 Jun 2021 | 29 Jul 2021 | 27 | 65% | 33% | 2% | 16% |
| 01 Jul 2020 - 31 Dec 2020 | 26 Jan 2021 | 29 | 65% | 32% | 3% | 19% |
| 01 Jan 2020 - 30 Jun 2020 | 29 Jul 2020 | 28 | 72% | 27% | 1% | 23% |
| 01 Jul 2019 - 31 Dec 2019 | 24 Jan 2020 | 28 | 70% | 27% | 3% | 24% |
| 01 Jan 2019 - 30 Jun 2019 | 30 Jul 2019 | 29 | 68% | 31% | 1% | 25% |
| 01 Jul 2018 - 31 Dec 2018 | 29 Jan 2019 | 28 | 67% | 30% | 3% | 24% |
| 01 Jan 2018 - 30 Jun 2018 | 27 Jul 2018 | 27 | 63% | 35% | 2% | 33% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
Standard terms range from immediate payment on receipt of invoices to 60 days on receipt of invoices
Were there any changes to the standard payment terms in the reporting period?
We have reduced our standard payment terms to 60 days as we had two suppliers that had standard payment terms of 90 days that we have not used since 2023. All other suppliers are within our standard payment terms stated above of 60 days
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
60
Suppliers can get in touch with Novo Nordisk Limited's Accounts Payable department for any invoice or payment queries via email. Disputes are managed directly with the supplier and resolved items are reprocessed. Novo Nordisk Limited is supported by a Global Business Service Centre Accounts Payable team who support suppliers with their queries.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Novo Nordisk Limited is the UK subsidiary of Novo Nordisk, a global healthcare group headquartered in Denmark that develops and supplies medicines for diabetes and other chronic diseases. Its registered SIC classification is wholesale of pharmaceutical goods, reflecting its role distributing the group's pharmaceutical products within the UK market. The wider Novo Nordisk group, founded in 1923, focuses on treatments for diabetes and related serious chronic conditions, reporting its financial results and R&D pipeline at group level. The UK entity is registered in Gatwick, West Sussex, and remains active, operating as part of the broader international corporate structure rather than as an independent manufacturer.
Generated from the company's website and Companies House records. Sources: novonordisk.com